Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 5, 2016, Pages 412-422

  Kubitza, Dagmar ^a   Berkowitz, Scott D ^b   Misselwitz, Frank ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

anticoagulant; evidence based medicine; pharmacodynamics; pharmacology; rivaroxaban

Indexed keywords

RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ACUTE CORONARY SYNDROME; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DRUG DOSE REGIMEN; ELIMINATION HALF-LIFE; HUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; THROMBOSIS; VENOUS THROMBOEMBOLISM; ADULT; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; EVIDENCE BASED MEDICINE; TREATMENT OUTCOME;

ADULT; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FACTOR XA INHIBITORS; HUMANS; RIVAROXABAN; TREATMENT OUTCOME;

EID: 84973167592     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616631427     Document Type: Article

References (56)

1. ® Summary of Product Characteristics. 2015. Web site. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed February 8, 2016.
2. Kreutz R,. A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. J Thromb Thrombolysis. 2014; 38 (2): 137-149.
3. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G,. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78 (4): 412-421.
4. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M,. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61 (12): 873-880.
5. Kubitza D, Becka M, Roth A, Mueck W,. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24 (10): 2757-2765.
6. Kubitza D, Becka M, Roth A, Mueck W,. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013; 53 (3): 249-255.
7. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007; 47 (11): 1398-1407.
8. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity: Errata. J Clin Pharmacol. 2008; 48 (11): 1368.
9. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010; 70 (5): 703-712.
10. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR,. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150 (9): 1881-1884.
11. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R,. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012; 28 (5): 669-680.
12. Kardas P,. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag. 2007; 3 (2): 235-242.
13. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012; 18 (7): 527-539.
14. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH,. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013; 126 (4): 357.
15. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011; 171 (9): 814-822.
16. Dahl OE,. Orthopaedic surgery as a model for drug development in thrombosis. Drugs. 2004; 64 (suppl 1): 17-25.
17. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007; 120 (5): 685-693.
18. Kubitza D, Becka M, Schwers S, Voith B,. Investigation of pharmacodynamic and pharmacokinetic interactions between rivaroxaban and enoxaparin in healthy male subjects. Clinical Pharm in Drug Dev. 2013; 2 (3): 270-277.
19. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI,. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133 (6 suppl): 141S-159S.
20. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006; 4 (1): 121-128.
21. Turpie AGG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005; 3 (11): 2479-2486.
22. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006; 114 (22): 2374-2381.
23. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358 (26): 2765-2775.
24. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358 (26): 2776-2786.
25. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373 (9676): 1673-1680.
26. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007; 116 (2): 180-187.
27. Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008; 112 (6): 2242-2247.
28. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005; 293 (6): 681-689.
29. van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007; 357 (11): 1094-1104.
30. Mueck W, Lensing AWA, Agnelli G, Décousus H, Prandoni P, Misselwitz F,. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50 (10): 675-686.
31. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363 (26): 2499-2510.
32. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366 (14): 1287-1297.
33. Morell J, Sullivan B, Khalabuda M, McBride BF,. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. J Clin Pharmacol. 2010; 50 (9): 986-1000.
34. Watson T, Shantsila E, Lip GYH,. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009; 373 (9658): 155-166.
35. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159 (3): 340-347.
36. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
37. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883-891.
38. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32 (19): 2387-2394.
39. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 (11): 1045-1057.
40. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357 (20): 2001-2015.
41. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 109 (4): 569-579.
42. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374 (9683): 29-38.
43. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366 (1): 9-19.
44. Mega JL, Braunwald E, Wiviott SD, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013; 112 (4): 472-478.
45. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104 (3): 633-641.
46. ® Summary of Product Characteristics. 2015. Web site. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002629/WC500189045.pdf. Accessed February 8, 2016.
47. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012; 107 (5): 925-936.
48. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369 (22): 2093-2104.
49. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D,. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5 (12): 2368-2375.
50. Botticelli Investigators, Buller H, Deitchman D, Prins M, Segers A,. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008; 6 (8): 1313-1318.
51. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012; 18 (3): 139-146.
52. Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS,. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012; 29 (8): 675-690.
53. Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015; 31 (10): 1831-1840.
54. McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-VKA oral anticoagulant medications based on the pharmacy quality alliance measure. Curr Med Res Opin. 2015; 31 (12): 2167-2173.
55. Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015; 17 (4): 530-538.
56. Beyer-Westendorf J, Ebertz F, Förster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015; 113 (6): 1247-1257.